These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3675610)

  • 1. Anti-aggregatory and contractile activity of analogues of prostaglandins E1, D1 and H1.
    Lysz TW; Felsen D; Sprecher H
    Biochem Pharmacol; 1987 Oct; 36(20):3533-5. PubMed ID: 3675610
    [No Abstract]   [Full Text] [Related]  

  • 2. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of platelet aggregation by prostaglandins and their fatty acid precursors: pharmacological basis for a therapeutic approach.
    Needleman P; Whitaker MO; Wyche A; Watters K; Sprecher H; Raz A
    Prostaglandins; 1980 Jan; 19(1):165-81. PubMed ID: 6247744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthetic studies on Prostanoids. XX. Synthesis of stable (+/-)-prostaglandin H1 analogs.
    Sakai K; Inoue K; Amemiya S; Morita A; Kojima K
    Chem Pharm Bull (Tokyo); 1980 Jun; 28(6):1814-9. PubMed ID: 7408058
    [No Abstract]   [Full Text] [Related]  

  • 6. Contractile effects of a PGH2 analog and PGD2 on intrapulmonary vessels.
    Gruetter CA; McNamara DB; Hyman AL; Kadowitz PJ
    Am J Physiol; 1978 Feb; 234(2):H139-45. PubMed ID: 623314
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of thromboxane receptors in human platelets.
    Jones RL; Wilson NH; Armstrong RA
    Adv Exp Med Biol; 1985; 192():67-81. PubMed ID: 3010674
    [No Abstract]   [Full Text] [Related]  

  • 8. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues.
    Morinelli TA; Niewiarowski S; Kornecki E; Figures WR; Wachtfogel Y; Colman RW
    Blood; 1983 Jan; 61(1):41-9. PubMed ID: 6293626
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets.
    Best LC; McGuire MB; Martin TJ; Preston FE; Russell RG
    Biochim Biophys Acta; 1979 Mar; 583(3):344-51. PubMed ID: 221045
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
    Mallarkey G; Smith GM
    Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting prostaglandin endoperoxide transformation: antibodies against PGH2.
    Fitzpatrick FA; Pike JE
    Prog Lipid Res; 1981; 20():179-82. PubMed ID: 7342082
    [No Abstract]   [Full Text] [Related]  

  • 12. Partial agonism of prostaglandin H2 analogs and 11-deoxy-prostaglandin F2 alpha to thromboxane-sensitive preparations.
    Jones RL; Wilson NH
    Adv Prostaglandin Thromboxane Res; 1980; 6():467-75. PubMed ID: 7386280
    [No Abstract]   [Full Text] [Related]  

  • 13. PGD3 is the mediator of the antiaggregatory effects of the trienoic endoperoxide PGH3.
    Whitaker MO; Needleman P; Wyche A; Fitzpatrick FA; Sprecher H
    Adv Prostaglandin Thromboxane Res; 1980; 6():301-3. PubMed ID: 6966885
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of prostaglandin I2 and analogs on platelet aggregation and smooth muscle contraction.
    Crane BH; Maish TL; Maddox YT; Corey EJ; Székely I; Ramwell PW
    J Pharmacol Exp Ther; 1978 Jul; 206(1):132-8. PubMed ID: 351171
    [No Abstract]   [Full Text] [Related]  

  • 15. Renal vascular effects of endoperoxide analogs, prostaglandins, and arachidonic acid.
    Feigen LP; Chapnick BM; Flemming JE; Flemming JM; Kadowitz PJ
    Am J Physiol; 1977 Nov; 233(5):H573-9. PubMed ID: 920820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triene prostaglandins: prostaglandin D3 and icosapentaenoic acid as potential antithrombotic substances.
    Whitaker MO; Wyche A; Fitzpatrick F; Sprecher H; Needleman P
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5919-23. PubMed ID: 230492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological effects of (+/-)-11-deoxy, 16-phenoxy-prostaglandin E1 derivatives in the cardiovascular system.
    Banerjee AK; Tuffin DP; Walker JL
    Br J Pharmacol; 1985 Jan; 84(1):71-80. PubMed ID: 3884073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2.
    Gorman RR; Fitzpatrick FA; Miller OV
    Biochem Biophys Res Commun; 1977 Nov; 79(1):305-13. PubMed ID: 200243
    [No Abstract]   [Full Text] [Related]  

  • 19. Action and metabolism of prostaglandins in the pulmonary circulation.
    Kadowitz PJ; Lippton HL; McNamara DB; Spannhake EW; Hyman AL
    Adv Prostaglandin Thromboxane Leukot Res; 1982; 10():333-56. PubMed ID: 6216787
    [No Abstract]   [Full Text] [Related]  

  • 20. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
    Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
    Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.